Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 MillionTORONTO, ON / ACCESSWIRE / February 6, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (\"FSD Pharma\" or the \"Company\"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, announced that the Court of Appeal for Ontario affirmed the Judgment entered by the Superior Court of Justice in the amount of CDN $2.81 million, plus $175,000, plus interest. An additional $5,000 in costs were awarded to FSD Pharma by the Court of Appeal in respect of Dr. Raza Bokhari's failed motion for leave to appeal. The Judgment confirmed Arbitration Awards in which the Arbitrator dismissed Dr. Raza Bokhari's claims for wrongful dismissal, and awarded FSD Pharma its fees and costs incurred in defending the arbitration. See FSD Pharma May 11, 2023 press release (https://feeds.issuerdirect.com/news-release.html?newsid=4924606685100137).In December 2023, FSD Pharma filed a Petition to Confirm Arbitration Awards in the United States District Court for the Eastern District of Pennsylvania. This begins the process by which FSD Pharma will collect from Dr. Raza Bokhari the amounts awarded by the Arbitrator.About FSD PharmaFSD is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc. (\"Lucid\"), FSD is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) (\"Lucid-MS\"). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD has also licensed UNBUZZD™, a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption for use in the consumer recreational sector, to Celly Nutrition Corp. (\"Celly Nu\") and is entitled to a royalty on the...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B